Literature DB >> 18628320

Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions.

D A Wilkinson1, M Kolar, P A Fleming, A D Singh.   

Abstract

The aim of this study was to compare dosimetric parameters between iodine-125 ((125)I) and ruthenium-106 ((106)Ru) plaques of similar sizes in the treatment of choroidal melanomas. The study design included retrospective double planning of each case. 26 consecutive patients with choroidal melanomas measuring 5 mm or less in thickness were included. Dose distributions were calculated using Plaque Simulator treatment-planning software for a prescription of 85 Gy to the tumour apex. Doses to the outer sclera, lens, fovea and optic disc were obtained for each case using appropriately sized plaques of each isotope. Statistical inferences were made using the non-parametric Wilcoxon signed rank test. The mean dose to the macula, disc and lens was 18%, 53% and 89% less, respectively, with (106)Ru than with (125)I. Scleral doses were greater for (106)Ru. The use of collaborative ocular melanoma study dosimetry results in even higher mean doses to the macula, disc, lens and sclera. Two-dimensional dose distributions and dose volume histograms demonstrated the increase in dose outside the tumour volume using (125)I. This comparison shows that, for tumours not exceeding 5 mm in thickness, the use of (106)Ru plaques has the potential to reduce the radiation dose to nearby normal structures and possibly lower the risk of radiation-induced visual loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628320     DOI: 10.1259/bjr/76813976

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  11 in total

1.  Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.

Authors:  Hasan Danish; Matthew J Ferris; Ehsan Balagamwala; Jeffrey M Switchenko; Kirtesh R Patel; Maria Choudhary; Caroline Craven; Pia Mendoza; John Suh; Chris Bergstrom; Hans E Grossniklaus; Thomas M Aaberg; Arun Singh; Ian R Crocker; Mohammad K Khan
Journal:  Melanoma Res       Date:  2018-04       Impact factor: 3.599

2.  (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.

Authors:  Christopher A Barker; Jasmine H Francis; Gil'ad N Cohen; Brian P Marr; Suzanne L Wolden; Beryl McCormick; David H Abramson
Journal:  Brachytherapy       Date:  2014-05-28       Impact factor: 2.362

3.  Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate.

Authors:  Masood Naseripour; Ramin Jaberi; Ahad Sedaghat; Zohreh Azma; Marzieh Nojomi; Khalil Ghasemi Falavarjani; Hossein Nazari
Journal:  J Contemp Brachytherapy       Date:  2016-02-09

4.  Gamma Knife radiosurgery for locally recurrent choroidal melanoma following plaque radiotherapy.

Authors:  Osama A Sorour; John E Mignano; Jay S Duker
Journal:  Int J Retina Vitreous       Date:  2018-06-13

5.  106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma.

Authors:  Ping Jiang; Konstantine Purtskhvanidze; Gerit Kandzia; Dirk Neumann; Ulf Luetzen; Frank-André Siebert; Johann Roider; Juergen Dunst
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

6.  Outcome Analysis of Visual Acuity and Side Effect after Ruthenium-106 Plaque Brachytherapy for Medium-sized Choroidal Melanoma.

Authors:  Tahra AlMahmoud; Sean Quinlan-Davidson; Gregory R Pond; Jean Deschênes
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Apr-Jun

Review 7.  Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis.

Authors:  Saeed Karimi; Amir Arabi; Zahra Siavashpour; Toktam Shahraki; Iman Ansari
Journal:  J Contemp Brachytherapy       Date:  2021-05-18

Review 8.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

9.  Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.

Authors:  Lisa Tarmann; Werner Wackernagel; Domagoj Ivastinovic; Mona Schneider; Peter Winkler; Gerald Langmann
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

10.  Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma.

Authors:  Luca Tagliaferri; Monica Maria Pagliara; Carlotta Masciocchi; Andrea Scupola; Luigi Azario; Gabriela Grimaldi; Rosa Autorino; Maria Antonietta Gambacorta; Antonio Laricchiuta; Luca Boldrini; Vincenzo Valentini; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.